Enzon halts Phase II colon cancer program
This article was originally published in Scrip
Executive Summary
Enzon Pharmaceuticals reported that it was halting development of PEG-SN38, also known as EZN-2208, in metastatic colorectal cancer, owing it to evolving standards of care for the disease.